Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Features

724 Features
PHASE IV CLINICAL TRIALS: Post Marketing Studies

19 Sep 06

Strategic Research Institute’s Phase IV Clinical Trials (PCT) conference features a fully packed informational two day event organized into a series of discussions focusing on the major Phase IV and Patient Recruitment/ Retention issues of today.
Amy Yueh

Pay for Performance: Strategies for Achieving Value and Improving Health Outcomes

19 Sep 06

GAIN VALUABLE INSIGHT INTO: • How CMS’ movement toward P4P will Impact Healthcare and Payors Nationwide • Large Employer HR Strategy: How Aligning Incentives and Creating a Health • Information Exchange will Reduce your Healthcare Spend • Health Plans: How Data, Transparency and Consumers will Affect your P4P Initiatives
Seth Fritts

Medicare Part D: What is the Future?

19 Sep 06

Highlights Include: Five Presentations from CMS including an Update on the 2007 Landscape Understanding the Short- and Long-Term Impact of Part D Strategies for Driving Senior Enrollment Innovative Approaches to Public & Private Partnerships Analyzing Patient Perceptions of Out-of-Pocket Costs The Importance of Pharmacoeconomic Data Securing Favorable Formulary Coverage in the Part D Environment The Future of Employer Plans
Amy Yueh

We are opening our doors here at i3

31 Aug 06

We would like to invite you to join us here at our offices in Maidenhead, Berkshire from 10.30 onwards to 14.30.
Sarah Kettlewell

Lean Documentation 5

30 Aug 06

In an earlier field report, we looked at some of the issues surrounding manufacturing process instructions (MPIs) and manufacturing process records (MPRs). I want to look at the issue of recording data in MPRs in more detail, as the format of your MPR has a huge impact on its usability and therefore the error rate.
PharmiWeb.com Field Reporter: Jo Hills

Movers and Shakers of the Pharma Industry - Paul Hawkins

23 Aug 06

Paul Hawkins, the General Secretary for the Health and Beauty Association, tells us his philosophy for career progression and how the H&BA’s new website will help them to progress. The website itself promotes HBA’s attempt to bring Health and Beauty companies together in debating and discussing how to develop and adapt the industry to meet changing customer and consumer needs. Paul hopes the move towards e-business will do just that.
Freya Eden-Ellis

Graduates Entering the Pharmaceutical Industry

22 Aug 06

You may not exactly be breaking into the gold vaults at Fort Knox, scaling the heights of MI5 à la James Bond or hacking into The Pentagon security system, but you want to enter the pharmaceutical industry, which can be nearly as difficult.
Freya Eden-Ellis

Candidate Profile: Paul Collins

09 Aug 06

Candidate Profile: Paul Collins Current Job Title: Clinical Project Manager II Department: Clinical Commenced with ICON: July 1997
Mike Wood, Freya Eden-Ellis

Movers and Shakers of the Pharma Industry - Andy Sarfas

08 Aug 06

Andy Sarfas is our mover and shaker of the week. He is the Global Internet Business Manager for Reckitt Benckiser.
Freya Eden-Ellis

Movers and Shakers of the Pharma Industry - David Mitchell

08 Aug 06

David Mitchell is the Commercial Director at McNeil Consumer Healthcare, a company that produces remedies for self-treatment available at pharmacies and supermarket stores.
Freya Eden-Ellis

Movers and Shakers of the Pharma Industry - Alex Bishop

08 Aug 06

Alex Bishop is the IT Business Manager at Pfizer, the largest supplier of medicines to the NHS.
Freya Eden-Ellis

Diverse challenges await generics industry

04 Aug 06

Because of the ever-increasing costs of healthcare provision the world over, many governments are enacting legislation to promote generic prescription in order to keep costs down. With drugs worth $160 billion in sales coming off patent by 2015, it would seem a good time to be in the generics industry. However the generics market is not without challenges.
Datamonitor

Lean Documentation 4

03 Aug 06

Manufacturing Instructions and Records: Operators are expected to follow manufacturing instructions to produce a product that meets the required specification. Typically these instructions will be written by technical experts, the chemical engineers who were responsible for the technology transfer, the process validation and so on.
PharmiWeb.com Field Reporter: Joanna Hills

Networking Tips

03 Aug 06

Networking: What is it and How do you do it?
Jim Melling - Field Reporter

Preparing for GCP Inspections: The Truth, the Whole Truth, and Nothing But the Truth

02 Aug 06

Every sponsor or CRO can expect their country’s regulatory agency to arrive on their premises periodically to conduct routine inspections. In the UK, for instance, the Medicines and Healthcare products Regulatory Agency (MHRA) conducts routine periodic inspections approximately every three years. Apart from these, the MHRA also conducts “for cause” and “follow up” inspections, and they also take part in the third-country inspection program. Because all inspections may be either announced or unan
Triona Coll

Elidel Eczema Cream: Dr Mark Ballard Answers Our Questions

01 Aug 06

Dr Mark Ballard, the Medical Director of Respiratory and Dermatology Therapeutic Areas at the Novartis Pharmaceuticals Corporation answers our questions about their eczema cream Elidel.
Freya Eden-Ellis

Call for guidelines on when to stop or continue drug treatment for Alzheimer’s Disease

01 Aug 06

Doctors taking part in a survey on Alzheimer’s Disease (AD) management have called for clear and consistent guidelines on diagnosis and treatment of the condition to be drawn up as a matter of urgency. The survey was sponsored by Eisai Europe Ltd and Pfizer Inc, who market the cholinesterase inhibitor Aricept (donepezil), and was presented during the International Conference on Alzheimer’s Disease and Related Disorders.
Olwen Glynn Owen – Pharmiweb Field Reporter

Sheltering under an Umbrella?

31 Jul 06

The Treasury is aware of a growing trend, which has recently moved into the pharmaceutical sector, for staff to be provided to clients through “umbrella” or “composite” companies. These companies promise a golden scenario of reduced costs to their clients and greater take-home pay to the individuals who work through them.
Claire Jackaman

New Tools for Mental Health Professionals: Computerised Cognitive Behavioural Therapy (CCBT) in Primary Care

25 Jul 06

Cognitive behaviour therapy (CBT) combines two very effective kinds of psychotherapy delivered face to face by medical therapists
Jim Melling - PharmiWeb Field Reporter

Lean Documentation 2b

25 Jul 06

In the last report we analysed part of an SOP control system for inefficiencies and opportunities for error, by mapping the system and asking ‘what if?’ at each stage. But, as we mentioned previously, documentation systems (or, indeed, any type of control system) rarely operate in isolation. So let’s look at some of the inputs and outputs there might be on a typical site, using the same process as before.
Joanna Hills - PharmiWeb Field Reporter

Lean Documentation 2

25 Jul 06

A well-run documentation system will support your business processes and improvements, not hold them back. How do you ensure that this is the case?
Joanna Hills - PharmiWeb Field Reporter

PowderMed: flying ahead in avian flu

21 Jul 06

PowderMed has submitted an application to UK regulators seeking to conduct human trials of its avian influenza vaccine. Developing an effective vaccine against the next influenza pandemic is a challenging task, but one many companies are taking on. However, until a virus able to cause a pandemic emerges, no one knows for certain which product will be most effective.
Datamonitor

Hints and Tips: Survive in the Work Place Part Two

19 Jul 06

Hints and Tips: Survive in the Work Place Part Two
Elaine Ford - PharmiWeb Field Reporter

Baraclude (entecavir) offers much-needed new option for chronic hepatitis B infection

11 Jul 06

Baraclude (entecavir), a new oral drug developed by Bristol-Myers Squibb, recently approved by the European Commission for treatment of chronic hepatitis B viral (HBV) infections, is expected to become available in a few months in some countries of the EU, the Middle East and Africa.
Olwen Glynn Owen - PharmiWeb Field Reporter

Tibotec and J&J cleared to launch Aptivus rival

11 Jul 06

The FDA has approved Tibotec and Johnson & Johnson's HIV drug Prezista, enabling it to join Boehringer Ingelheim's recently launched Aptivus as one of just two second-generation protease inhibitors currently available. However, competition will be fierce as both drugs target similar patients in a crowded market where small differences in marketing approaches could impact hugely on sales.
Datamonitor

New data results for Roche cancer drug Xeloda impressive

10 Jul 06

ROCHE is set to file for a new indication for its oral, targeted cancer drug Xeloda® following impressive new data presented at the American Society of Clinical Oncology conference (ASCO).
Rhonda Siddall,

Biomarin advance novel antihypertensive...Researchers identify novel molecular target for the treatment of sepsis

07 Jul 06

Todays Headlines from across the DailyUpdates network (July 7th, 2006) - In today's edition we highlight Biomarin's development of the novel antihypertensive 6R-BH4 and new research describing a promising molecular target for future sepsis therapeutics.
LeadDiscovery

Phase 2 testing commences on Abiogen's anxiolytic ABIO 0801...Novel drug delivery technology facilitating the use of therapeutic macromolecules

05 Jul 06

Todays Headlines from across the DailyUpdates network (from DailyUpdates 5th July)- Although press releases are quite thin on the ground today because of the July 4th holiday in the US, Abiogen have released important information regarding the start of phase 2 testing of the company's anxiolytic, ABIO 08/01. In addition we feature a review describing a potentially groundbreaking drug delivery technology. This technology harnesses protein transduction domains (PTDs), endogenous peptide sequences
LeadDiscovery

New clinical data on Vasogen's heart failure candidate...Johnson and Johnson publish on potential asthma candidate

27 Jun 06

Todays Headlines from across the DailyUpdates network - Today we feature news from Vasogen on their candidate treatment of chronic heart failure plus new data from Johnson & Johnson on a new integrin antagonist that may underly a future treatment of asthma
LeadDiscovery

ArQule moves forward with their cell cycle modulator...Wyeth develops selective GABA(A) alpha2/alpha3 subtype agonists as candidate anxiolytics

21 Jun 06

Todays Headlines from across the DailyUpdates network (20th June, 2006): We highlight research from Merck who are developing a novel approach to anxiety and news from ArQule on their oncology candidate
LeadDiscovery

Advertising